Jonathan Appleby

Chief Scientific Officer • Cell and Gene Therapy Catapult

Dr Jonathan Appleby is currently Chief Scientific Officer at the UK’s Cell and Gene Therapy Catapult (CGT Catapult).  The CGT Catapult employs over 400 full time staff, spread across four sites.  Dr Appleby leads the London based 1200m2 development laboratories which are focused on the creation of analytical and process development solutions for ATMPs. Prior to joining the CGT Catapult Jonathan was Chief Scientific Officer for cell and gene therapy in GSK’s Rare Diseases Unit where he was accountable for the EU Submission of StrimvelisTM, the first paediatric CD34 Stem Cell Gene Therapy to be licensed anywhere in the world. He was also project leader for a similar asset focused on Metachromatic Leukodystrophy which was licenced to Orchard Therapeutics in 2018 and later approved in Europe.

Jonathan has 20 years’ experience of R&D and has worked in all phases of drug development across a broad range of therapeutic areas.

Also speaking

Mustafa Munye

Director R&D Operations • Complement Therapeutics

John Campbell

Director, Tissues Cells & Advanced Therapeutics • Scottish National Blood Transfusion Service

Rachel Yao

Associate Director Technical Operations • SOTIO Biotech Inc

Event Info


Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.

2022 Post-Event Report

Download the post-event report for Advanced Therapies Europe 2022.